炎症性肠病的治疗药物研究进展

Research Progress in Therapeutic Drugs for Inflammatory Bowel Disease

炎症性肠病是一种慢性肠道炎症性疾病,包括溃疡性结肠炎和克罗恩病,易导致严重的消化吸收障碍,病情反复,需终身治疗,严重影响患者的生活及心理健康。传统的治疗药物主要有氨基水杨酸制剂、糖皮质激素、免疫抑制药等。随着对其发病机制研究的不断深入,针对发病机制而开发的新兴药物有TNF-α抑制药、抗黏附生物制剂、白细胞介素(IL)-12/IL-23抑制药,以及一系列的小分子药物,如Janus激酶(JAK)抑制药、鞘氨醇-1-磷酸受体调节药、磷酸二酯酶4抑制药等。此外,非药物治疗和辅助治疗也在逐渐显示其独特的优势。本文针对炎症性肠病治疗药物的研究进展进行综述,以期为临床治疗方案和药物研发提供依据。

Inflammatory bowel disease is a chronic inflammatory disorder of gastrointestinal tract,including ulcerative colitis and Crohn’s disease,which can lead to serious disorders of digestive and absorption,recurrent conditions and lifelong treatment,and seriously affectes the life and psychology of patients.The traditional therapeutic drugs mainly include aminosalicylic acid preparations,glucocorticoids,immunosuppressants and so on.With the in-depth study of its pathogenesis,new drugs developed for the pathogenesis include TNF-αinhibitors,anti-adhesion biological agents,IL-12/IL-23 inhibitors,and a series of small molecular drugs,such as JAK inhibitors,sphingosine-1-phosphate receptor modulators,as well as phosphodiesterase 4 inhibitors.In addition,non-drug therapy and adjuvant therapy are gradually showing their unique advantages.This article reviewed the research progress in the drugs for the treatment of inflammatory bowel disease in order to provide basis for clinical treatment and drug research and development.